Egyesült Államok - angol - NLM (National Library of Medicine)

bryant ranch prepack - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have be

Egyesült Államok - angol - NLM (National Library of Medicine)

bryant ranch prepack - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have be

Egyesült Államok - angol - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 2.5 mg

Egyesült Államok - angol - NLM (National Library of Medicine)

ascend laboratories, llc - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol capsules are indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. dronabinol capsules are contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)]. risk summary dronabinol capsules, a synthetic cannabinoid, may cause fetal harm. avoid use of dronabinol capsules in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations]. cannabinoids have be

Banglades - angol - DGDA (Directorate General of Drug Administration)

nabin laboratory (unani) - neem - capsule

Banglades - angol - DGDA (Directorate General of Drug Administration)

nabin laboratory (unani) - chirata - capsule

Banglades - angol - DGDA (Directorate General of Drug Administration)

nabin laboratory (unani) - etrifal zamani - semi-solid

Banglades - angol - DGDA (Directorate General of Drug Administration)

nabin laboratory (unani) - qurs hazmol - tablet

Egyesült Államok - angol - NLM (National Library of Medicine)

abbvie inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 2.5 mg - marinol is indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. marinol is contraindicated in patients with a history of a hypersensitivity reaction to dronabinol or sesame oil. reported hypersensitivity reactions to dronabinol capsules include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing and throat tightness [see adverse reactions (6.2)] . marinol, a synthetic cannabinoid, may cause fetal harm. avoid use of marinol in pregnant women. although there is little published data on the use of synthetic cannabinoids during pregnancy, use of cannabis (e.g., marijuana) during pregnancy has been associated with adverse fetal/neonatal outcomes [see clinical considerations] . cannabinoids have been found in the umbilical cord blood from pregnant women who s

Egyesült Államok - angol - NLM (National Library of Medicine)

insys therapeutics, inc. - dronabinol (unii: 7j8897w37s) (dronabinol - unii:7j8897w37s) - dronabinol 5 mg in 1 ml - syndros is indicated in adults for the treatment of: - anorexia associated with weight loss in patients with acquired immune deficiency syndrome (aids). - nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. syndros is contraindicated in patients: - with a history of a hypersensitivity reaction to dronabinol. reported hypersensitivity reactions to dronabinol include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, throat tightness [see adverse reactions (6.2)] . - with a history of a hypersensitivity reaction to alcohol. - who are receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days [see warning and precautions (5.3)] . syndros contains 50% (w/w) dehydrated alcohol and 5.5% (w/w) propylene glycol. risk summary syndros, a synthetic cannabinoid containing alcohol, may cause fetal harm. avoid use of syndros in pregnant women. although there is l